Altea, KAI Enter Development Pact

Altea Therapeutics has entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides using Altea’s PassPort Transdermal Delivery System.

Altea has granted KAI an option to receive a worldwide technology license for further development and commercialization of these transdermal products. Should KAI exercise the option, it will fund all product development, manufacturing and commercialization, while Altea will receive license payments, development and commercialization milestones and royalties on sales.

“We are pleased to enter into this agreement with KAI Pharmaceuticals,” said Dr. Eric Tomlinson, Ph.D., DSc, president and chief executive officer of Altea Therapeutics. “The agreement further validates the broad application of the Altea Therapeutics novel transdermal patch technology for the transdermal delivery of water-soluble compounds. While we continue to apply our transdermal technology to currently approved drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates and small molecules, this new partnership allows us to apply our technology to the new peptide drugs being developed by KAI Pharmaceuticals.”